Gastritis is a disease of inflammation, not a disease of acid
This is the distinction that most Indian gastritis patients are never given. The burning in the upper abdomen feels like acid. It often is, in part, acid contacting inflamed mucosal tissue. But the inflammation producing that tissue vulnerability is not caused by acid. It is caused by a bacterial-driven immune response that runs on entirely separate biology.
The proof is in the outcome data. In TumGard's survey of 20,363 Indian adults with gut symptoms, 54% were on antacids or PPIs and still symptomatic. That 54% is not a compliance failure. It is a mismatch between the problem and the tool being used to address it.
The NF-kB inflammatory cascade, step by step
NF-kB (nuclear factor kappa B) is the master transcription factor for the inflammatory response in human cells. Under normal conditions it is kept inactive, bound to inhibitory IκB proteins. When a threat signal arrives, IκB is degraded, NF-kB enters the nucleus, and it switches on the genes for inflammatory cytokine production.
In H. pylori-driven gastritis, this switch is activated by multiple pathways simultaneously: CagA toxin injection activates NF-kB directly; outer membrane proteins trigger NF-kB through pattern recognition receptors; bacterial peptidoglycan fragments activate NOD1 receptors that feed into the same NF-kB pathway.[1] The result is sustained NF-kB activation for as long as H. pylori is present — which, without intervention, is indefinitely.
The cytokine output — what NF-kB actually produces
Once NF-kB is active in gastric epithelial cells, it drives the transcription of a specific set of pro-inflammatory cytokines. These are the molecules that translate the bacterial signal into physical mucosal damage:
IL-8 is the primary mediator in the gastric setting — it is the cytokine most closely associated with the neutrophil-rich "active" inflammation pattern visible on endoscopy biopsy.[2] The clinical term "chronic active gastritis" essentially describes tissue with elevated NF-kB activity, high IL-8 output, and dense neutrophil infiltration.
Where acid fits — and where it doesn't
Acid is not irrelevant to gastritis. When the mucus layer thins — because goblet cells are being damaged by the inflammatory cascade — the underlying epithelium is exposed to stomach acid at a concentration it isn't designed to handle. The result is burning pain. Reducing acid with a PPI reduces the severity of that pain.
What it does not do:
- Acid output from parietal cells
- Burning sensation from acid-on-tissue
- Short-term symptom relief
- NF-kB activation by H. pylori
- IL-8 cytokine production
- Neutrophil infiltration and tissue damage
- TNF-α epithelial cell apoptosis
- EGFR/ERK repair pathway suppression
When a PPI is stopped, acid returns — often at higher than normal levels due to parietal cell hyperplasia. The inflamed, thinned mucosa is still there. The H. pylori-driven NF-kB cascade is still running. Nothing has changed structurally, so symptoms return rapidly. The medication was suppressing the symptom, not addressing the biology.
Why quercetin's NF-kB inhibition is relevant
Quercetin — a flavonoid found in significant concentrations in onions, capers, and several medicinal plants — inhibits NF-kB activation through multiple mechanisms: it stabilises IκB (the inhibitory protein that keeps NF-kB inactive), inhibits the IκB kinase (IKK) complex that normally triggers NF-kB release, and reduces reactive oxygen species that act as secondary NF-kB activation signals.[3]
In gastric tissue models, quercetin supplementation at relevant concentrations reduces IL-8 transcription and decreases neutrophil migration into the mucosal tissue — producing measurable reductions in the "active" inflammation markers seen on endoscopy. This is not anti-acid activity. It is anti-inflammatory activity at the primary molecular switch.
Quercetin inhibits NF-kB in gastric epithelial cells at concentrations achievable through supplementation, reducing the transcription of IL-8 and TNF-α — the primary cytokines responsible for mucosal damage in chronic active H. pylori-driven gastritis. This mechanism is distinct from acid suppression and operates on the inflammatory cascade directly.
The downstream effect on mucosal repair
NF-kB inhibition does more than reduce direct damage. IL-1β — one of the cytokines NF-kB drives — is also the primary suppressor of the EGFR/ERK mucosal repair pathway and prostaglandin E2 synthesis. By reducing IL-1β output, quercetin-mediated NF-kB inhibition simultaneously reduces tissue damage and removes the suppressive signal blocking repair. The lining's own regenerative machinery can resume function.
References
- Crowe SE. Helicobacter pylori infection. New England Journal of Medicine. 2019;380(12):1158–1165. PMID 30699316. Documents the multiple NF-kB activation pathways from H. pylori — CagA, OipA, NOD1, and outer membrane proteins — foundational to the cascade described in this article.
- Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defence and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41–60. PMID 18424695. Describes IL-8-driven neutrophil infiltration as the defining feature of "active" gastritis; establishes IL-1β as the key suppressor of prostaglandin E2 and EGFR/ERK signalling.
- Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. Modulating role of nuclear factor-κB in the gastroprotective action of flavonoids. Journal of Ethnopharmacology. 2023. PMID 36842733. Documents quercetin's NF-kB inhibitory mechanism in gastric epithelial tissue — the primary mechanistic basis for this article's discussion of flavonoid intervention.
- Gutierrez-Grijalva EP, Picos-Salas MA, Leyva-Lopez N et al. Biological activities of flavonoids and related compounds. International Journal of Molecular Sciences. 2021. PMID 26797645. Provides additional documentation of quercetin IκB stabilisation and IKK inhibition mechanisms — the specific molecular routes by which quercetin prevents NF-kB nuclear translocation.
- Merlin Annie Raj, RD. TumGard India Gut Health Report 2026. Hugg Beverages Pvt. Ltd. 2026. tumgard.com/india-gut-health-report-2026. Source of the 54% medicated-but-still-symptomatic figure cited in this article. Total survey n=20,363.
The 54% rate of medicated-but-still-symptomatic respondents is consistent with published data showing PPI inadequacy as a long-term solution for H. pylori-driven gastritis in Indian primary care settings (Crowe, NEJM 2019). The cytokine functions described in the table are established consensus findings documented in Laine et al. 2008 and Crowe 2019. The quercetin NF-kB inhibitory mechanism is documented in Ye et al. 2023 and Gutierrez-Grijalva et al. 2021 — two independent peer-reviewed sources for the same mechanistic claim.